Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.130
Poster Session (Poster presentations categorized by each organ) P3
6
2
Yayoi Honda, Risa Goto, Nami Idera, Kazumi Horiguchi, Dai Kitagawa, Hiromi Miyamoto, Tomoyuki Aruga, Toshinari Yamashita, Katsumasa Kuroi Division of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
abstracts
Background: It is known that age, KPS and subtype are important prognostic factors, and the Graded Prognostic Assessment (GPA) has been previously reported to clarify prognosis for brain metastases (BM) patients by the other investigators.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v103/2240399 by guest on 24 October 2019
PROGNOSTIC SIGNIFICANCE OF SUBTYPES AND GPA (GRADED PROGNOSTIC ASSESSMENT) IN BRAIN METASTASES FROM BREAST CANCER
Method: Sixty-six patients with BM were included. We examined the clinical characteristics by primary tumor subtype; ER + /HER2- (LM), ER + or-/HER2+ (Her2-potitive), ER-/HER2- (TN), and GPS scores were calculated according to Breast cancer specific GPA (BCS-GPA). Results: The number of LM, Her2-positive, TN tumors were 26, 21, 19, respectively. In patients with Her2-positive tumors, the number of brain metastasis tended to be single and there were only a few patients with meningitis. Median survival after BM in patients with LM, Her2-positive, TN tumors were 11, 37, 3 months, respectively. Prognosis of patients with TN tumors was significantly poor (vs. Her2 p < 0.001), and prognosis of patients with Her2-positive tumors tended to be longer as compared with those with LM ( p = 0.188). GPA scores were 0-1 in 8 cases, 1.5-2 in 19 cases, 2.5-3 were 24 cases, 3.5-4were 15 cases, and median survivals were 3, 8, 10, 40 months, respectively. Conclusions: Our reports suggested that the pattern and prognosis of BM appear to be dependent on subtype and GPA score would have prognostic significance and might be useful for decision making.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email:
[email protected].